Svolos P, Reddick W E, Edwards A, Sykes A, Li Y, Glass J O, Patay Z
From the Departments of Diagnostic Imaging (P.S., W.E.R., A.E., J.O.G., Z.P.).
Biostatistics (A.S., Y.L.), St. Jude Children's Research Hospital, Memphis, Tennessee.
AJNR Am J Neuroradiol. 2017 Jun;38(6):1235-1241. doi: 10.3174/ajnr.A5159. Epub 2017 Apr 20.
Assessing the response to treatment in infiltrative brain tumors by using lesion volume-based response criteria is challenging. We hypothesized that in such tumors, volume measurements alone may not accurately capture changes in actual tumor burden during treatment. We longitudinally evaluated volume changes in both normal-appearing supratentorial white matter and the brain stem lesions in patients treated for diffuse intrinsic pontine glioma to determine to what extent adjuvant systemic therapies may skew the accuracy of tumor response assessments based on volumetric analysis.
The anatomic MR imaging and diffusion tensor imaging data of 26 patients with diffuse intrinsic pontine glioma were retrospectively analyzed. Treatment included conformal radiation therapy in conjunction with vandetanib and dexamethasone. Volumetric and diffusion data were analyzed with time, and differences between time points were evaluated statistically.
Normalized brain stem lesion volume decreased during combined treatment (slope = -0.222, < .001) and increased shortly after completion of radiation therapy (slope = 0.422, < .001). Supratentorial white matter volume steadily and significantly decreased with time (slope = -0.057, < .001).
Longitudinal changes in brain stem lesion volume are robust; less pronounced but measurable changes occur in the supratentorial white matter. Volume changes in nonirradiated supratentorial white matter during the disease course reflect the effects of systemic medication on the water homeostasis of normal parenchyma. Our data suggest that adjuvant nontumor-targeted therapies may have a more substantial effect on lesion volume changes than previously thought; hence, an apparent volume decrease in infiltrative tumors receiving combined therapies may lead to overestimation of the actual response and tumor control.
使用基于病变体积的反应标准评估浸润性脑肿瘤的治疗反应具有挑战性。我们假设,在此类肿瘤中,仅体积测量可能无法准确反映治疗期间实际肿瘤负荷的变化。我们纵向评估了接受弥漫性脑桥内在胶质瘤治疗的患者幕上正常白质和脑干病变的体积变化,以确定辅助全身治疗在多大程度上可能影响基于体积分析的肿瘤反应评估的准确性。
回顾性分析26例弥漫性脑桥内在胶质瘤患者的解剖磁共振成像和扩散张量成像数据。治疗包括适形放疗联合凡德他尼和地塞米松。对体积和扩散数据进行时间分析,并对时间点之间的差异进行统计学评估。
联合治疗期间脑干病变体积归一化值下降(斜率=-0.222,P<.001),放疗完成后不久增加(斜率=0.422,P<.001)。幕上白质体积随时间稳步且显著下降(斜率=-0.057,P<.001)。
脑干病变体积的纵向变化显著;幕上白质的变化虽不明显但可测量。疾病过程中未接受照射的幕上白质体积变化反映了全身用药对正常实质水平衡的影响。我们的数据表明,辅助性非肿瘤靶向治疗对病变体积变化的影响可能比之前认为的更大;因此,接受联合治疗的浸润性肿瘤体积明显减小可能导致对实际反应和肿瘤控制的高估。